These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33148516)

  • 21. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
    Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
    Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.
    Ma X; Hui H; Jin Y; Dong D; Liang X; Yang X; Tan K; Dai Z; Cheng Z; Tian J
    Biomaterials; 2016 May; 87():46-56. PubMed ID: 26897539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.
    Adams SR; Yang HC; Savariar EN; Aguilera J; Crisp JL; Jones KA; Whitney MA; Lippman SM; Cohen EE; Tsien RY; Advani SJ
    Nat Commun; 2016 Oct; 7():13019. PubMed ID: 27698471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
    Davis JA; Rock DA; Wienkers LC; Pearson JT
    Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoplasmic reticulum-targeted glutathione and pH dual responsive vitamin lipid nanovesicles for tocopheryl DM1 delivery and cancer therapy.
    Wang YQ; Ji MY; Wang C
    Int J Pharm; 2020 May; 582():119331. PubMed ID: 32289484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, Characterization and Anti-Cancer Therapeutic Potential of Withanolide-A with 20nm sAuNPs Conjugates Against SKBR3 Breast Cancer Cell Line.
    Tabassam Q; Mehmood T; Raza AR; Ullah A; Saeed F; Anjum FM
    Int J Nanomedicine; 2020; 15():6649-6658. PubMed ID: 32982224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
    Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
    Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.
    Goldmacher VS; Audette CA; Guan Y; Sidhom EH; Shah JV; Whiteman KR; Kovtun YV
    PLoS One; 2015; 10(2):e0117523. PubMed ID: 25671541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitubulin activities of ansamitocins and maytansinoids.
    Ikeyama S; Takeuchi M
    Biochem Pharmacol; 1981 Sep; 30(17):2421-5. PubMed ID: 21043240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. α
    Zhong P; Meng H; Qiu J; Zhang J; Sun H; Cheng R; Zhong Z
    J Control Release; 2017 Aug; 259():176-186. PubMed ID: 27986551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Technology evaluation: C242-DM1, ImmunoGen Inc.
    Smith S
    Curr Opin Mol Ther; 2001 Apr; 3(2):198-203. PubMed ID: 11338934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies.
    Kumar V; Bhatt PC; Rahman M; Kaithwas G; Choudhry H; Al-Abbasi FA; Anwar F; Verma A
    Int J Nanomedicine; 2017; 12():6747-6758. PubMed ID: 28932118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
    Walles M; Rudolph B; Wolf T; Bourgailh J; Suetterlin M; Moenius T; Peraus G; Heudi O; Elbast W; Lanshoeft C; Bilic S
    Drug Metab Dispos; 2016 Jul; 44(7):897-910. PubMed ID: 27122302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer.
    Tang P; Sun Q; Yang H; Tang B; Pu H; Li H
    Int J Pharm; 2018 Jul; 545(1-2):74-83. PubMed ID: 29715531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties.
    Bellat V; Lee HH; Vahdat L; Law B
    Biomacromolecules; 2016 Jun; 17(6):2040-9. PubMed ID: 27180972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
    Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
    Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
    Liu C; Tadayoni BM; Bourret LA; Mattocks KM; Derr SM; Widdison WC; Kedersha NL; Ariniello PD; Goldmacher VS; Lambert JM; Blättler WA; Chari RV
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8618-23. PubMed ID: 8710920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.